A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson From Real-World Experience - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 8. doi: 10.1111/dom.14052. Online ahead of print. A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson

Concise Advice on Inpatient Diabetes during COVID-19 - Guidelines for managing DKA using subcutaneous insulin Version 3.3 29/4/2020 Page 1 COncise adVice on Inpatient Diabetes (COVID:Diabetes): GUIDELINE FOR MANAGING DKA USING SUBCUTANEOUS INSULIN (where intravenous insulin infusion is not possible) NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP* o For use in Covid-19 suspected/positive people and those without Covid-19 disease when diagnosis of DKA has been confirmed (see ? COVID (...) Inpatient Network – COVID-19 • Designed by: Leicester Diabetes CentreVersion 3.3 29/4/2020 Page 2 BASAL INSULIN o ALWAYS START/CONTINUE LONG-ACTING INSULIN WHEN TREATING DKA › If using regular injectable long-acting insulin this should be continued › If not previously using basal insulin initiate a dose of 0.15* units/kg/day (involve the local diabetes team at the earliest opportunity) If using a personal insulin pump either: 1. Continue basal insulin rate via pump if person can safely manage

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) - PubMed This site needs JavaScript to work (...) : Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Mar 24;dc192232. doi: 10.2337/dc19-2232. Online ahead of print. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Centre, Institute for Clinical

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 15;dc192452. doi: 10.2337/dc19-2452. Online ahead of print. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2

Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Mar 12. doi: 10.1111/dom.14028. Online ahead of print. Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial

Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where

Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission insulin glargine/lixisenatide (Suliqua ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with metformin for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal

Insulin Aspart (Fiasp) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions 2020 Feb 19 [Online ahead of print] Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins , , , , , , , , , , Affiliations Expand Affiliations 1 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver

Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study To compare the safety and efficacy of U500-R delivered by a novel, specifically designed U500-R insulin pump with U-500R delivered by multiple daily injections (MDI).The phase 3 VIVID study randomized people with type 2 diabetes to U-500R by continuous subcutaneous insulin infusion (CSII) or MDI. Participants (aged 18-85 years) had HbA1c ≥7.5 (...) % and ≤12.0% and a total daily dose of insulin >200 and ≤600 U/day. After a 2-week transition to three times daily injections of U-500R, participants were treated for 24 weeks with U-500R by CSII or MDI. Treatment arms were compared using mixed model repeated measures analysis.The study randomized 420 participants (CSII: 209, MDI: 211) with 365 completers. Mean changes from baseline were: HbA1c, -1.27% (-13.9 mmol/mol) with CSII and -0.85% (-9.3 mmol/mol) with MDI (difference - 0.42% [-4.6 mmol/mol], P

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012 (...) . Estimated treatment differences for insulin dose (-13.01 U) and body weight change (-1.57 kg) significantly favoured IDegLira. The hypoglycaemia rate was 44% lower with IDegLira versus IGlar U100. Safety results were similar. In a trial resembling clinical practice, more participants receiving IDegLira than IGlar U100 met treatment targets, supporting use of IDegLira as an initial injectable therapy for people with T2D uncontrolled on OADs and eligible for insulin initiation.© 2020 The Authors. Diabetes

Sotagliflozin with insulin for treating type 1 diabetes Sotagliflozin with insulin for treating type 1 diabetes T echnology appraisal guidance Published: 12 February 2020 www.nice.org.uk/guidance/ta622 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 6 [Online ahead of print] Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study Similar Glycaemic Control and Less Hypoglycaemia During Active Titration After Insulin Initiation With Glargine 300 units/mL and Degludec 100 units/mL: A Subanalysis of the BRIGHT Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Oct 23 [Online ahead of print] Similar Glycaemic Control and Less Hypoglycaemia During Active Titration After Insulin Initiation

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome (...) collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double (...) . 7.1% with placebo; mostly mild to moderate).Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.© 2019 by the American Diabetes Association.

Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes.In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 (...) as the primary end point.The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL (P = 0.170). The proportion of time in hypoglycemia <70 mg/dL was 0.0% for both groups. Baseline-adjusted interstitial prandial glucose increments 1 h after meals were greater in Faster-CL compared with Standard-CL (P = 0.017). The gaps between measured plasma insulin and estimated insulin-on-board levels at the beginning, at the end, and 2 h after the exercise

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D).Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial.Among 176 (...) randomized participants (HDV-L n = 118, LIS n = 58), the difference in change from baseline A1C was 0.09% (95% CI -0.18% to 0.35%), confirming noninferiority (prespecified margin ≤0.4%). Overall, there were no statistically significant differences between treatments for hypoglycemia or insulin dosing. However, baseline A1C modified the treatment group effect (interaction P < 0.001) on clinically apparent hypoglycemia designated by treatment-blinded investigators as severe. Thus, at higher baseline A1C

The relationships between hemoglobin and insulin resistance, glucose effectiveness, and first- and second-phase insulin secretion in adult Chinese. We denote the four major factors related to the development of type 2 diabetes (T2D) as "diabetes factor" (DF); increased insulin resistance (IR); decreased glucose effectiveness (GE); and the first-and-second-phase of insulin secretion (FPIS, SPIS). The level of hemoglobin (Hb) was found to be related to IR and FPIS, but no-known studies focused (...) , it was IR. Both phases of insulin secretion had relatively weaker relationships than IR and GE.